Table 3.
Meta-analysis results for associations of MSI/BRAF mutation status with RFS/PFS in colorectal cancer
| Groups | N | HR | HRlci | HRuci | PHR | Model | I2 (%) | Pheter | PBegg | PEgger |
|---|---|---|---|---|---|---|---|---|---|---|
| RFS | ||||||||||
| MSSmut/MSSwt | 4 | 1.543 | 1.159 | 2.053 | 2.978E-03 | F | 0.0 | 5.499E-01 | 3.077E-01 | 2.388E-01 |
| MSIwt/MSSwt | 3 | 0.505 | 0.308 | 0.828 | 6.728E-03 | F | 0.0 | 7.906E-01 | 2.983E-01 | 3.043E-01 |
| MSImut/MSSwt | 2 | 0.535 | 0.302 | 0.943 | 3.235E-02 | F | 0.0 | 4.131E-01 | ||
| MSImut/MSSmut | 2 | 0.233 | 0.069 | 0.783 | 1.827E-02 | F | 0.0 | 5.120E-01 | ||
| PFS | ||||||||||
| MSSmut/MSSwt | 4 | 1.452 | 1.020 | 2.067 | 3.845E-02 | R | 60.4 | 5.554E-02 | 3.077E-01 | 4.938E-01 |
| MSIwt/MSSwt | 4 | 1.453 | 0.920 | 2.294 | 1.096E-01 | R | 58.3 | 6.579E-02 | 7.339E-01 | 9.647E-01 |
| MSImut/MSSwt | 1 | 1.380 | 1.070 | 1.770 | 1.207E-02 | |||||
| MSImut/MSIwt | 4 | 1.061 | 0.505 | 2.232 | 8.729E-01 | R | 52.5 | 9.704E-02 | 7.339E-01 | 8.668E-01 |
| MSIwt/MSSmut | 1 | 0.990 | 0.790 | 1.240 | 9.283E-01 | |||||
| MSImut/MSSmut | 4 | 0.958 | 0.618 | 1.486 | 8.493E-01 | F | 33.7 | 2.096E-01 | 7.339E-01 | 7.859E-01 |
Note: Bold, statistically significant.
Abbreviations: HRlci, lower 95% CI of HR; HRuci, upper 95% CI of HR; MSI, microsatellite instability; MSImut, microsatellite instability and BRAF mutation; MSIwt, microsatellite instability and BRAF wild type; MSSmut, microsatellite stable and BRAF mutation; MSSwt, microsatellite stable and BRAF wild type; R, random-effects model; F, fixed-effects model; PFS, progression-free survival; RFS, recurrence-free survival.